Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland

Show full item record



Permalink

http://hdl.handle.net/10138/228671

Citation

Soini , E , Asseburg , C , Taiha , M , Puolakka , K , Purcaru , O & Luosujärvi , R 2017 , ' Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland ' , Advances in Therapy , vol. 34 , no. 10 , pp. 2316-2332 . https://doi.org/10.1007/s12325-017-0614-8

Title: Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland
Author: Soini, Erkki; Asseburg, Christian; Taiha, Maarit; Puolakka, Kari; Purcaru, Oana; Luosujärvi, Riitta
Contributor: University of Helsinki, HYKS erva
University of Helsinki, Clinicum
Date: 2017-10
Language: eng
Number of pages: 17
Belongs to series: Advances in Therapy
ISSN: 0741-238X
URI: http://hdl.handle.net/10138/228671
Abstract: To model the American College of Rheumatology (ACR) outcomes, cost-effectiveness, and budget impact of certolizumab pegol (CZP) (with and without a hypothetical risk-sharing scheme at treatment initiation for biologic-na <ve patients) versus the current mix of reimbursed biologics for treatment of moderate-to-severe rheumatoid arthritis (RA) in Finland. A probabilistic model with 12-week cycles and a societal approach was developed for the years 2015-2019, accounting for differences in ACR responses (meta-analysis), mortality, and persistence. The risk-sharing scheme included a treatment switch and refund of the costs associated with CZP acquisition if patients failed to achieve ACR20 response at week 12. For the current treatment mix, ACR20 at week 24 determined treatment continuation. Quality-adjusted life years were derived on the basis of the Health Utilities Index. In the Finnish target population, CZP treatment with a risk-sharing scheme led to a estimated annual net expenditure decrease ranging from 1.7% in 2015 to 5.6% in 2019 compared with the current treatment mix. Per patient over the 5 years, CZP risk sharing was estimated to decrease the time without ACR response by 5%-units, decrease work absenteeism by 24 days, and increase the time with ACR20, ACR50, and ACR70 responses by 5%-, 6%-, and 1%-units, respectively, with a gain of 0.03 quality-adjusted life years. The modeled risk-sharing scheme showed reduced costs of a,notsign7866 per patient, with a more than 95% probability of cost-effectiveness when compared with the current treatment mix. The present analysis estimated that CZP, with or without the risk-sharing scheme, is a cost-effective alternative treatment for RA patients in Finland. The surplus provided by the CZP risk-sharing scheme could fund treatment for 6% more Finnish RA patients.
Subject: Biological therapies
Certolizumab pegol
Disease-modifying antirheumatic drugs
Health economics
Health policies
Rheumatoid arthritis
Rheumatology
MODIFYING ANTIRHEUMATIC DRUGS
5-YEAR FOLLOW-UP
QUALITY-OF-LIFE
COST-EFFECTIVENESS
EULAR RECOMMENDATIONS
PRODUCTIVITY COSTS
DISEASE-ACTIVITY
2013 UPDATE
REGISTER
BURDEN
3121 General medicine, internal medicine and other clinical medicine
317 Pharmacy
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
10.1007_s12325_017_0614_8.pdf 933.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record